Read-Gene
2005
FOUNDED
PUBLIC
STATUS
21-30
EMPLOYEES
RDG
STOCK SYMBOL
$0.27
SHARE PRICE
(As of Friday Closing)
Description
Read-Gene SA treats each patient individually based on genetic tests. The company's segments include chemoprevention, clinical trials and genetic tests. It also engaged in developing technologies to commercialize methods to detect, prevent and treat malignant tumours.
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Stock Exchange
WAR
Primary Office
- Ul. Alabastrowa 8
- Grzepnica, 72-003
- Poland
+48 91 000 00 00
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Read-Gene’s full profile, request a free trial.
Read-Gene Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $0.15 - $0.27 | $3.24M | $0.26 | 883.33 | 11.8M |
Read-Gene Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
FY 2015
31-Dec-2015
|
|---|---|---|---|---|
| Enterprise Value | 2,996 | 4,455 | 3,423 | 3,474 |
| Revenue | 966 | 1,270 | 1,318 | 429 |
| EBITDA | (122) | 53 | (36) | 292 |
| Net Income | (150) | 14 | (125) | (180) |
| Total Assets | 4,465 | 5,226 | 4,288 | 3,629 |
| Total Debt | 0 | 0 | 0 | 189 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer